Tvardi Therapeutics
Tvardi Therapeutics Begins Phase 2 Trial for Novel IPF Treatment
Anika Sharma
Tvardi Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing STAT3 inhibitors, has exciting news to share. They’ve initiated the dosing ...
Initiation of Treatment with TTI-101, Either Alone or in Combination with Standard Targeted Therapy, in Advanced Hepatocellular Carcinoma
SG Tylor
Source – Tvardi Therapeutics On June 22, 2023 the initial administration of TTI-101, either as a monotherapy or in combination ...
